Malignant Pleural Effusion Global Market Report 2025
The Business Research Company’s Malignant Pleural Effusion Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034
— The Business Research Company
LONDON, GREATER LONDON, UNITED KINGDOM, May 13, 2025 /EINPresswire.com/ — The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights – Market Sizing & Forecasts Through 2034
The malignant pleural effusion market has demonstrated robust growth over recent years, currently valued at $4.42 billion in 2024 with predictions to rise to $4.74 billion in 2025. This growth draws from an elevated worldwide adoption of indwelling pleural catheters, increasing clinical trials, greater reimbursement availability, and a disturbing rise in metastatic malignancies.
Is the Malignant Pleural Effusion Market Set to Witness Substantial Growth?
An impressive compound annual growth rate CAGR of 7.1% is accompanying this surge. As per the report, the market size will continue to rise at a steady pace, reaching $6.17 billion in 2029 at a CAGR of 6.8%. This trend is being bolstered by increasing investments in healthcare infrastructure, solid government support, rising numbers of cancer survivors, heightening demand for home-based care and promising developments in liquid biopsy.
Technological advancements are setting the tone for the forecast period like the integration of artificial intelligence in imaging tools, advancements in targeted cancer therapies, improvements in pleurodesis, upgrades in biomarkers, and quickening trials for novel therapeutic agents. Encouragingly, these prospects accompany the ongoing expansion of healthcare infrastructure, offering enhanced accessibility, quality, and efficiency of care.
Get Your Free Sample Market Report:
What is driving the growth in the malignant pleural effusion market?
A significant factor driving the malignant pleural effusion market is the increasing cases of lung cancer. This disease, characterized by the uncontrolled growth of abnormal cells in the lungs, forms tumors and disrupts normal lung function. The main culprit behind the rise in lung cancer cases is the usage of tobacco and cigarettes, causing extensive damage to lung tissues and increasing the probability of the disease.
An unsettling prognosis is that malignant pleural effusion indicates advanced stages of lung cancer, leading to even worse respiratory functions. As per the American Cancer Society, the estimated number of new lung and bronchus cancer cases tallied up to 236,740 in 2022 and 238,340 in 2023, providing sufficient impetus for the growth of the malignant pleural effusion market.
What is the impact of improving healthcare infrastructure on the malignant pleural effusion market?
Concurrently, improved healthcare infrastructure is expected to rapidly propel the market further. Enhanced diagnosis, treatment, accessibility of medical technologies and specialized care, and more equipped healthcare facilities contribute significantly to the management of malignant pleural effusion. As of May 2023, the American Health Care Association reported that the number of hospitals in the US increased by 0.591% from the previous year, escalating from 6,093 to 6,129.
Order Your Report Now For A Swift Delivery:
Which major companies are leading the malignant pleural effusion market?
Key industry players in this market include Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., and Ewimed GmbH.
What are the latest trends in the malignant pleural effusion industry?
Innovative therapies such as enzyme-targeting therapy are currently being developed to improve cancer treatment results. It involves creating specific drugs to inhibit or modify the activities of disease-related enzymes. For instance, in September 2022, the biotechnology company, RS Oncology, LLC, initiated the MITOPE clinical trial in the UK. The Phase 1/2 trial is assessing the performance of RSO-021, an inhibitor designed to target oxidative stress to eliminate cancer cells while preserving healthy tissues in the treatment of malignant pleural effusion and mesothelioma.
How is the malignant pleural effusion market segmented?
The malignant pleural effusion market report segments include:
1 By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter
2 By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy
3 By End Users: Hospitals, Ambulatory Clinics, Other End Users
Subsegments include:
1 By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2 By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis
3 By Thoracic Drainage And Pleurodesis:Chemical Pleurodesis, Mechanical Pleurodesis, Biological Pleurodesis
4 By Indwelling Pleural Catheter:Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter
Which regions are leading in the malignant pleural effusion market?
Based on regions, North America had the largest share in the market in 2024. However, the report predicts that Asia-Pacific will be the fastest-growing region in coming years. The report also covers other major regions including Western Europe, Eastern Europe, South America, the Middle East, and Africa.
Browse Through More Similar Reports By The Business Research Company:
Malignant Melanoma Treatment Global Market Report 2025
Adult Malignant Glioma Therapeutics Global Market Report 2025
Breast Cancer Diagnostics Global Market Report 2025
About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company:
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn:
YouTube:
Global Market Model: global-market-model
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Article originally published on www.einpresswire.com as Growth Drivers, Share, And Trends
